AMGN vs CLDI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and CLDI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and CLDI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company based in San Diego, California, developing therapies that combine oncolytic viruses with cell-based delivery to target hard-to-treat cancers. Its approach is built on the idea of shielding therapeutic viruses inside stem cells so they can survive the immune system long enough to reach and destroy tumors. The pipeline includes CLD-101 (NeuroNova), studied in Phase 1 for high-grade glioma, an aggressive brain cancer; CLD-201 (SuperNova), an allogeneic stem-cell-loaded viral therapy for solid tumors such as soft tissue sarcoma, triple-negative breast cancer, and head and neck cancer; and RTNova (CLD-400), an earlier-stage systemic platform using an enveloped virotherapy designed for intravenous, potentially redosable delivery to metastatic and lung cancers. The company generates no product revenue and is years away from any potential approval.

Full CLDI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
• CLDI drivers: Stem-Cell-Shielded Virotherapy Platform; CLD-201 SuperNova and FDA Designations.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For CLDI, calidi is a pre-revenue, clinical-stage micro-cap whose value depends almost entirely on early-stage trial outcomes, so a single clinical failure, safety signal, or program delay could sharply reduce the stock.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMGN if you believe its drivers more; CLDI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and CLDI guides.

AMGN. Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

CLDI. A pre-revenue clinical biotech like Calidi cannot be valued on earnings, because there are none; metrics like P/E are not meaningful. Investors who study these companies typically weigh the cash runway against the quarterly burn rate, the timing and probability of upcoming clinical catalysts (such as trial starts, data readouts, and FDA designations), and the dilution required to fund the next stage of development. For Calidi specifically, the very low cash balance, going-concern doubt, reverse split, and heavy warrant overhang mean financing risk and dilution are central to any assessment, and the stock can swing dramatically on capital raises as much as on science.

Headline figures (approximate, early 2026): AMGN shows revenue (ttm) ~$33-35 billion (approximate, verify), operating margin ~30%+ (approximate, verify), p/e (ttm) ~20-25x (GAAP varies; approximate, verify), dividend yield ~3% (approximate, verify); CLDI shows revenue None (no approved products; pre-revenue clinical-stage), net loss (fy 2025) ~$25.6 million (vs. ~$23.8 million in 2024), cash & equivalents ~$5.6 million at year-end 2025; ~$6.9 million cash and restricted cash at March 31, 2026, cash runway Very limited; company has flagged substantial doubt about going concern and relies on ongoing financings.

AMGN and CLDI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMGN and CLDI exposure against your real portfolio. It is not an investment adviser.